Qiagen sales, earnings climb in Q3

By LabPulse.com staff writers

October 13, 2020 -- Significant ongoing demand for COVID-19 testing and improved trends in other areas of Qiagen's product portfolio led to a 26% increase in preliminary net sales for the company during its third quarter.

For the period (end-September 30), Qiagen expects to report net sales of $481.3 million, up 26% at both actual and constant exchange rates from the $382.7 million produced in the third quarter of 2019. Non-COVID-19 testing products declined at only a mid-single-digit rate compared with the same period a year ago.

Qiagen said that preliminary adjusted earnings per share (EPS) are approximately $0.58 at constant exchange rates, up from adjusted EPS of $0.36 in the third quarter of 2019. Full results will be reported on November 4.

Qiagen closes NeuMoDx deal
Qiagen has acquired the remaining 80.1% of diagnostics instruments company NeuMoDx Molecular for $248 million in cash. The deal rounds out Qiagen's...
Qiagen to launch rapid portable SARS-CoV-2 antigen test
Qiagen plans to launch the Access Anti-SARS-CoV-2 antigen test, a rapid portable test that can detect novel coronavirus antigens in people with active...
Qiagen launches 10-minute SARS-CoV-2 test
Qiagen announced the U.S. launch of a new digital SARS-CoV-2 detection test that can be done on a portable device. The device provides results in about...
Qiagen appoints new supervisory board chairman
Qiagen has appointed Lawrence Rosen as the new chairman of its supervisory board, effective immediately. The news comes in the wake of the failure of...
Thermo Fisher's acquisition of Qiagen falls short
Thermo Fisher Scientific has terminated its acquisition of Qiagen after the company was unable to secure the number of shares needed to proceed with the...

Copyright © 2020 LabPulse.com

Last Updated ls 10/13/2020 5:07:02 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current